We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00964756
Recruitment Status : Completed
First Posted : August 25, 2009
Last Update Posted : February 13, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
In spite of surgical and chemotherapeutic advances, long term survival for advanced and recurrent gynecologic cancers remains dismal and no curative treatment for recurrent disease exists. Novel treatment strategies are needed. This is a study to determine the maximally tolerated dose of and toxicities associated with intraperitoneal delivery of an infectivity enhanced adenovirus that expresses a suicide gene and an gene that allows imaging of gene transfer. This vector will be given in combination with intravenous ganciclovir in patients with recurrent ovarian and other gynecological cancers.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Genetic: Ad5.SSTR/TK.RGD Drug: Ganciclovir (GCV) Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of AD5.SSTR/TK.RGD; A Tropism Modified Adenovirus Vector for Intraperitoneal Delivery of Therapeutic Genes and Additional Capability of Noninvasive Imaging of Gene Transfer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (Infectivity Enhanced Adenoviral Vectors for Ovarian CA)
Study Start Date : August 2009
Primary Completion Date : December 2010
Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Ganciclovir
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Gene therapy Genetic: Ad5.SSTR/TK.RGD
Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
Drug: Ganciclovir (GCV)
GVC Day 5-18 IV 5 mg/kg BID all groups

Outcome Measures

Primary Outcome Measures :
  1. Evaluation for toxicity [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Molecular Studies for evaluation of gene transfer and generation of wild type adenovirus, viral shedding and clinical efficacy [ Time Frame: 30 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically documented invasive epithelial ovarian, extraovarian, fallopian tube or endometrial carcinoma.
  • Patients must have persistent or recurrent disease after standard debulking/staging surgery and conventional therapy.
  • Patients must have evidence of intraabdominal disease; disease may be measurable or nonmeasurable.
  • Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy of greater than 3 months.
  • Patients must have adequate hematologic, renal, and hepatic function defined as:

    • WBC > 3,000 ul
    • Granulocytes > 1,500 ul
    • Platelets > 100,000
    • Creatinine clearance > 80 mg/dl or serum creatinine > 2.0
    • Serum transaminases < 2.5 x upper limits of normal
    • Normal serum bilirubin
    • PT/PTT/INR < 1.5 x institutional ULN
    • O2 saturation > or = 92 %
  • Patients must be 19 years or older and must have signed informed consent

Exclusion Criteria:

  • Patients with epithelial tumors of low malignant potential, stromal tumors and germ cell tumors of the ovary are ineligible to participate in the study.
  • Patients with the only site of disease located beyond the abdominal cavity are ineligible to participate in the study.
  • Patients who are pregnant or lactating are ineligible to participate in the study.
  • Patients with a GOG performance status of 3 or 4 are ineligible to participate in the study.
  • Patients with active heart disease (characterized by angina, unstable arrhythmia, congestive heart failure or EF < 55%, pulmonary hyper- tension, active or chronic debilitating pulmonary disease(i.e., active pneumonia, severe COPD, pulmonary edema, O2 saturation < 92%), or coagulation disorders (i.e. bleeding disorders, or on therapeutic anti- coagulants)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964756

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
National Cancer Institute (NCI)
Principal Investigator: Ronald D Alvarez, MD University of Alabama at Birmingham
More Information

Responsible Party: Ronald D. Alvarez, Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00964756     History of Changes
Other Study ID Numbers: F080807013 (UAB 0821)
5R01CA090547-02 ( U.S. NIH Grant/Contract )
OGCA Link # 000137326 ( Other Identifier: UAB )
UAB 0821 ( Other Identifier: UAB Department )
First Posted: August 25, 2009    Key Record Dates
Last Update Posted: February 13, 2013
Last Verified: February 2013

Keywords provided by Ronald D. Alvarez, University of Alabama at Birmingham:
ovarian cancer
Recurrent ovarian cancer and other gynecologic cancers

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antiviral Agents
Anti-Infective Agents